PMID: 6103440May 24, 1980Paper

Peroperative blood-transfusion improve cadaveric renal-allograft survival in non-transfused recipients. A prospective controlled clinical trial

Lancet
K A WilliamsP J Morris

Abstract

The effect of peroperative transfusion was studied in 27 patients who had never had a blood-transfusion or been pregnant and who were receiving their first cadaver renal allograft. 13 patients in the treatment group were given 2 units of whole stored blood at transplantation, whereas 14 patients in the control group were given no blood. Actuarial analysis after 2 years showed a graft survival of 85% at 1 year in the treated group compared with 34% at 1 year in the control group (p = 0.03). Transfusion of non-transfused patients during transplantation may be as effective as pregraft transfusion.

Citations

Jul 11, 1981·Lancet·C Taylor, W P Faulk
May 5, 1983·The New England Journal of Medicine·Y VanrenterghemP Michielsen
Dec 1, 1985·British Journal of Haematology·D P SingalM A Blajchman
May 1, 1982·Immunology Today·P M Johnson
Aug 1, 1995·The British Journal of Surgery·G GozzettiM Masetti
Dec 1, 1984·Controlled Clinical Trials·C L MeinertK Higgins
Jan 1, 1982·Immunological Reviews·P J Morris, A Ting
Oct 1, 1980·Scottish Medical Journal·R F WoodH H Dick
May 26, 2009·Journal of Surgical Oncology·Elijah DixonJean-Nicolas Vauthey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.